Home LiteratureArticle Details
PMID: 19487948 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.

Epidemiology (Cambridge, Mass.) ·Vol. 20 ·No. 4 ·2009-07-00 ·Pages 512-22

Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA

Abstract

Adjusting for large numbers of covariates ascertained from patients' health care claims data may improve control of confounding, as these variables may collectively be proxies for unobserved factors. Here, we develop and test an algorithm that empirically identifies candidate covariates, prioritizes covariates, and integrates them into a propensity-score-based confounder adjustment model. We developed a multistep algorithm to implement high-dimensional proxy adjustment in claims data. Steps include (1) identifying data dimensions, eg, diagnoses, procedures, and medications; (2) empirically identifying candidate covariates; (3) assessing recurrence of codes; (4) prioritizing covariates; (5) selecting covariates for adjustment; (6) estimating the exposure propensity score; and (7) estimating an outcome model. This algorithm was tested in Medicare claims data, including a study on the effect of Cox-2 inhibitors on reduced gastric toxicity compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). In a population of 49,653 new users of Cox-2 inhibitors or nonselective NSAIDs, a crude relative risk (RR) for upper GI toxicity (RR = 1.09 [95% confidence interval = 0.91-1.30]) was initially observed. Adjusting for 15 predefined covariates resulted in a possible gastroprotective effect (0.94 [0.78-1.12]). A gastroprotective effect became stronger when adjusting for an additional 500 algorithm-derived covariates (0.88 [0.73-1.06]). Results of a study on the effect of statin on reduced mortality were similar. Using the algorithm adjustment confirmed a null finding between influenza vaccination and hip fracture (1.02 [0.85-1.21]). In typical pharmacoepidemiologic studies, the proposed high-dimensional propensity score resulted in improved effect estimates compared with adjustment limited to predefined covariates, when benchmarked against results expected from randomized trials.

MeSH Terms
Aged Aged, 80 and over Algorithms Anti-Inflammatory Agents, Non-Steroidal/adverse effects,therapeutic use Confounding Factors, Epidemiologic Cyclooxygenase 2 Inhibitors/adverse effects,therapeutic use Female Humans Insurance Claim Review/statistics & numerical data Male Medicare/statistics & numerical data Pharmacoepidemiology/statistics & numerical data Risk Assessment Treatment Outcome United States Upper Gastrointestinal Tract/drug effects
Chemicals
Anti-Inflammatory Agents, Non-Steroidal Cyclooxygenase 2 Inhibitors
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Schneeweiss Sebastian
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. [email protected]
Rassen Jeremy A
Glynn Robert J
Avorn Jerry
Mogun Helen
Brookhart M Alan
References (33)
33 references, click to expand
  1. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Arch Intern Med. 2000 Oct 23;160(19):2998-3003 PMID: 11041909
  2. Impact of mis-specification of the treatment model on estimates from a marginal structural model.
    Stat Med. 2008 Aug 15;27(18):3629-42 PMID: 18254127
  3. Confounding and misclassification.
    Am J Epidemiol. 1985 Sep;122(3):495-506 PMID: 4025298
  4. Revisiting the behavioral model and access to medical care: does it matter?
    J Health Soc Behav. 1995 Mar;36(1):1-10 PMID: 7738325
  5. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
    Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):444-53 PMID: 16761308
  6. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?
    Med Care. 2005 Oct;43(10):951-9 PMID: 16166864
  7. An application of propensity score matching using claims data.
    Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76 PMID: 15651087
  8. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Arthritis Rheum. 2006 Nov;54(11):3390-8 PMID: 17075817
  9. Variable selection and raking in propensity scoring.
    Stat Med. 2007 Feb 28;26(5):1022-33 PMID: 16708347
  10. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Aliment Pharmacol Ther. 2005 Mar 1;21(5):591-8 PMID: 15740543
  11. Estimating exposure effects by modelling the expectation of exposure conditional on confounders.
    Biometrics. 1992 Jun;48(2):479-95 PMID: 1637973
  12. Invited commentary: variable selection versus shrinkage in the control of multiple confounders.
    Am J Epidemiol. 2008 Mar 1;167(5):523-9; discussion 530-1 PMID: 18227100
  13. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
    Arthritis Res Ther. 2005;7(3):R644-65 PMID: 15899051
  14. Variable selection for propensity score models.
    Am J Epidemiol. 2006 Jun 15;163(12):1149-56 PMID: 16624967
  15. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.
    J Clin Epidemiol. 2006 May;59(5):437-47 PMID: 16632131
  16. Confounding by indication.
    Epidemiology. 1996 Jul;7(4):335-6 PMID: 8793355
  17. Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases".
    J Clin Epidemiol. 2007 Jul;60(7):648-50 PMID: 17573976
  18. The effect of misclassification in the presence of covariates.
    Am J Epidemiol. 1980 Oct;112(4):564-9 PMID: 7424903
  19. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.
    Med Care. 2007 Oct;45(10 Supl 2):S131-42 PMID: 17909372
  20. A review of uses of health care utilization databases for epidemiologic research on therapeutics.
    J Clin Epidemiol. 2005 Apr;58(4):323-37 PMID: 15862718
  21. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Circulation. 2004 May 4;109(17):2068-73 PMID: 15096449
  22. Efficacy and safety of statin monotherapy in older adults: a meta-analysis.
    J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):879-87 PMID: 17702880
  23. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.
    Stat Med. 2000 May 15;19(9):1141-64 PMID: 10797513
  24. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.
    J Clin Epidemiol. 2006 Aug;59(8):819-28 PMID: 16828675
  25. Quantifying biases in causal models: classical confounding vs collider-stratification bias.
    Epidemiology. 2003 May;14(3):300-6 PMID: 12859030
  26. Recall accuracy for prescription medications: self-report compared with database information.
    Am J Epidemiol. 1995 Nov 15;142(10):1103-12 PMID: 7485055
  27. Evaluating medication effects outside of clinical trials: new-user designs.
    Am J Epidemiol. 2003 Nov 1;158(9):915-20 PMID: 14585769
  28. Spurious effects from an extraneous variable.
    J Chronic Dis. 1966 Jun;19(6):637-47 PMID: 5966011
  29. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database.
    Epidemiology. 1996 Jan;7(1):101-4 PMID: 8664388
  30. Use of propensity score technique to account for exposure-related covariates: an example and lesson.
    Med Care. 2007 Oct;45(10 Supl 2):S143-8 PMID: 17909373
  31. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
    J Clin Epidemiol. 2005 Jan;58(1):98-102 PMID: 15649677
  32. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience.
    J Clin Epidemiol. 2000 Dec;53(12):1248-57 PMID: 11146272
  33. Use of automated databases for pharmacoepidemiology research.
    Epidemiol Rev. 1990;12:87-107 PMID: 2286228
Article Info
Journal
Epidemiology (Cambridge, Mass.)
Abbr.
Epidemiology
ISSN
1531-5487
Published
2009-07-00
Pages
512-22
Language
English
Region
United States
NLM ID
9009644
PMCID
PMC3077219
Subset
IM
Grants
NLM NIH HHS · R01 LM010213 · United States
NIMH NIH HHS · U01 MH078708 · United States
NIA NIH HHS · R01 AG021950-01 · United States
NIA NIH HHS · R01 AG023178-02 · United States
NIMH NIH HHS · R01-MH078708 · United States
NIA NIH HHS · R01-AG023178 · United States
NIA NIH HHS · K25 AG027400 · United States
NIMH NIH HHS · U01 MH078708-01 · United States
NIA NIH HHS · R01-AG018833 · United States
NIA NIH HHS · R01 AG021950 · United States
NIA NIH HHS · R01 AG018833 · United States
NIA NIH HHS · R01 AG018833-02 · United States
NIA NIH HHS · R01-AG021950 · United States
NIA NIH HHS · R01 AG023178 · United States
NIA NIH HHS · K25 AG027400-02 · United States
NIA NIH HHS · R01-AG027400 · United States
Corrections
CommentIn
ErratumIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]